CTRI/2024/05/067358尚未招募2 期
An open label randomized study to compare the effect of kushtadi churna and pippalyadi churna pratisarana in tundikeri vis-a-vis chronic tonsillitis
Dr MD Shahid Musaib0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects presenting with lakshanas of Tundikeri
- •Subjects presenting with signs and symptoms of chronic Tonsillitis
排除标准
- •1. Tonsillitis associated with complications such as peritonsillar abscess, parapharyngeal abscess, Tonsillar cyst, tonsilloliths
- •2. Subjects associated with other systemic disorders which intervene with the course of treatment
研究者
相似试验
尚未招募
2 期
A Clinical Study To Compare The Effect Of Kanadya Churna (Medicated powder)Pratisarana With And Without Irimedadi Taila (Medicated oil) Gandusha In Sheetada (Bleeding Gums)CTRI/2024/08/072142Dr Roshini R
尚未招募
2 期
A clinical study to compare the effect of marichadi anjana [medicated collyrium] and saugata anjana [medicated collyrium] in dwitiya patalagta timira [presbyopia]CTRI/2024/08/072216Dr Kasturi Aloni
进行中（未招募）
不适用
A Randomized, Open-Label, Study to Compare the Efficacy and Safety of AT1001 and Enzyme Replacement Therapy (ERT) in Patients With Fabry Disease and AT1001-Responsive GLA Mutations, Who Were Previously Treated With ERT - AT1001-012MedDRA version: 14.1Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersFabry diseaseEUCTR2010-022636-37-ITAMICUS THERAPEUTICS, INC50
招募中
3 期
A clinical study to compare the oral dose of Glucosamine HCl Tablet SR (Medreich) with Glucosamine HCl Tablet in patients with Osteoarthritis.CTRI/2010/091/000416Medreich Steri Lab P Ltd50
进行中（未招募）
不适用
A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled Colistimethate Sodium and nebulised TNSFI (Tobramycin nebuliser solution for inhalation, TOBI®) in cystic fibrosis patients with pseudomonas aeruginosa lung infectioPseudomonas aeruginosa (PA) infection in patients with cystic fibrosis.EUCTR2004-003675-36-BEForest Laboratories UK Ltd360